CLOSE

Dialog Box

Loading...

Grants

Maddie Riewoldt’s Vision aims to lead the globe in funding innovative medical research that translates into paradigm shifts in the treatment and health outcomes for young Australians living with Bone Marrow Failure Syndromes.

WHAT WE DO

We have already started funding cutting edge medical research into finding a cure for Bone Marrow Failure. To achieve this vision, we are working with a highly reputable Grants committee to develop National research strategy. We work Nationally to fund the research projects and people who we believe will find the breakthroughs this area of medicine so urgently needs.

 

Grants Committee

Professor David Ritchie

Chair

Professor David Ritchie is a Haematologist and Bone Marrow transplant specialist at the Royal Melbourne Hospital. He undertook his medical training and PhD in Immunology at the University of Otago before moving to Melbourne 10 years ago. He is head of the Bone Marrow Transplant Service of Royal Melbourne Hospital. He runs two research laboratories and is involved in all aspects of research into blood and bone marrow conditions. He is the immediate past president of the Haematology Society of Australia and New Zealand and is heavily involved in training young haematologists and medical researchers.

 

Professor David Haylock

Professor David Haylock brings considerable expertise in the isolation, characterization and ex vivo manipulation of human haemopoietic stem and progenitor cells to this initiative. Specifically, Professor Haylock has developed serum-free cytokine dependent culture systems for ex vivo expansion of haemopoietic stem cells (HSC) that enable analysis of the effect of purified recombinant cytokines on the proliferation and differentiation of HSC. Furthermore, he has significant skills in flow cytometric methods for multiparameter immunophenotypic analysis and fluorescent activated sorting of rare cell subsets. Recently, in collaboration with Professors Elefanty and Stanley (Monash University), this has involved detailed immunophenotypic characterisation of putative haemopoietic stem cells derived from differentiated hESC cultures. In addition, through his direction of the CRC-Polymers biomaterials project Prof Haylock has developed knowledge and expertise on biomaterials and bioreactor based systems for expansion of haemopoietic stem and progenitor cells.  This includes the development of modified polymer surfaces that facilitate immobilisation of biological ligands for cell expansion. These skills and expertise will be utilised in development of novel systems for propagating megakaryocytes and producing platelets from hESC derived precursors. 

 

Professor Suzanne Crowe AM 

Professor Suzanne Crowe AM is a physician-scientist holding positions as the Associate Director of Burnet Institute, Consultant Infectious Diseases Physician at The Alfred hospital and Adjunct Professor of Infectious Diseases, Monash University. She also holds positions as a Non-Executive Director on the boards of St Vincent’s Health Australia and Avita Medical. Professor Crowe was appointed a Member of the Order of Australia (AM) in 2011, recognised for her service to HIV/AIDS medicine as an academician, clinician and researcher. She was appointed a Fellow of the Australian Academy of Health and Medical Sciences in 2015.  

 

DR RACHEL CONYERS

Dr Rachel Conyers is a paediatric, adolescent and young adult malignant haematologist/oncologist. Dr Conyers completed her medical degree at Monash University in 2003. Completing fellowships in Paediatric Oncology at The Royal Children’s Hospital (Melbourne), Bone Marrow Transplantation (Great Ormond Street Hospital, London) and Adolescent Young Adult Sarcoma (University College Hospital, London). Returning to Australia in 2010, Rachel began an Adult and Adolescent fellowship in Haematology at Peter MacCallum Cancer Centre whilst completing her PhD in sarcoma pharmacogenomics and genetics. In 2016 Dr Conyers was awarded a Clinician Scientist Fellowship at Murdoch Children’s Research Institute (2016-2019). This research fellowship will allow her to continue her research into the genetic predisposition to chemotherapy side effects (mainly anthracycline cardiomyopathy). In 2016 Dr Conyers also co-founded Treat Unique, an Adolescent and Young Adult Oncology and Haematology service in the private sector. Currently Rachel works as a Bone Marrow Transplant Physician at The Royal Children’s Hospital and in Adult and Young Adult Haematology at the Victorian Comprehensive Cancer Centre, Parkville.